Karyopharm Therapeutics Inc (KPTI)

07:17 AM

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference | KPTI Stock News - GuruFocus

07:17 AM

07:00 AM

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - PR Newswire

07:00 AM

May 16, 2025

StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World

May 16, 2025

May 16, 2025

Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World

May 16, 2025

May 16, 2025

Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World

May 16, 2025

May 16, 2025

Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN

May 16, 2025

May 15, 2025

Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks

May 15, 2025

May 15, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025

May 15, 2025

Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World

May 15, 2025

May 15, 2025

Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus

May 15, 2025

May 14, 2025

KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus

May 14, 2025

May 14, 2025

Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks

May 14, 2025

May 14, 2025

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire

May 14, 2025

May 13, 2025

KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus

May 13, 2025

May 13, 2025

RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada

May 13, 2025

May 13, 2025

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga

May 13, 2025

May 13, 2025

KPTI Misses Q1 Revenue Estimates but Advances Myelofibrosis Tria - GuruFocus

May 13, 2025

May 13, 2025

KPTI Stock Boosted as Barclays Raises Price Target to $10 | KPTI - GuruFocus

May 13, 2025

May 13, 2025

Karyopharm (KPTI) Target Price Reduced by RBC Capital | KPTI Sto - GuruFocus

May 13, 2025

May 13, 2025

KPTI: Baird Lowers Price Target but Maintains Outperform Rating - GuruFocus

May 13, 2025

May 13, 2025

Karyopharm (KPTI) Price Target Reduced by Baird, Outperform Rati - GuruFocus

May 13, 2025

May 13, 2025

Karyopharm Therapeutics Inc Reports Q1 2025 Earnings: EPS Loss o - GuruFocus

May 13, 2025

May 13, 2025

RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating - marketscreener.com

May 13, 2025

May 13, 2025

Barclays Updates Karyopharm (KPTI) Price Target, Eyes Future Dat - GuruFocus

May 13, 2025

May 13, 2025

Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ... - Yahoo Finance

May 13, 2025

May 13, 2025

Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlig - GuruFocus

May 13, 2025

May 13, 2025

Karyopharm Q1 2025 slides: Myelofibrosis opportunity takes center stage By Investing.com - Investing.com Canada

May 13, 2025

May 13, 2025

Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress - TipRanks

May 13, 2025

May 12, 2025

Earnings call transcript: Karyopharm Q1 2025 shows mixed market reaction By Investing.com - Investing.com Nigeria

May 12, 2025

May 12, 2025

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modificati - Citizen Tribune

May 12, 2025

May 12, 2025

Earnings call transcript: Karyopharm Q1 2025 shows mixed market reaction - Investing.com

May 12, 2025

May 12, 2025

KPTI Projects Funding into Early 2026 Supported by XPOVIO Sales - GuruFocus

May 12, 2025

May 12, 2025

Karyopharm Reports First Quarter 2025 Financial Results and Anno - GuruFocus

May 12, 2025

May 12, 2025

Karyopharm Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025

May 12, 2025

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 12, 2025

May 12, 2025

Karyopharm Q1 2025 slides: Myelofibrosis opportunity takes center stage - Investing.com

May 12, 2025

May 12, 2025

Karyopharm Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025

May 12, 2025

Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView

May 12, 2025

May 12, 2025

Karyopharm Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 12, 2025

May 12, 2025

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 - Longview News-Journal

May 12, 2025

May 10, 2025

Investor Network: Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

May 10, 2025

May 08, 2025

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 | KPTI Stock News - GuruFocus

May 08, 2025

May 07, 2025

Redefining Myelofibrosis Care: Can Karyopharm's Selinexor Lead The Way? - RTTNews

May 07, 2025

May 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizen Tribune

May 01, 2025

May 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus

May 01, 2025

Apr 30, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Apr 30, 2025

Apr 29, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Here’s Why - Defense World

Apr 29, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025